GlaxoSmithKline has signed a five-year contract with the Department of Defense, worth up to $41 million.
The contract for $41 million to develop new antibiotics aimed at fighting bacteria resistant to current ones.
The UK based company will identify and develop a new class of antibacterials to target potential biothreat outbreaks and hospital-acquired infections.
The pharmaceutical company will provide supplemental staff and will cover other program costs.
The company said the research will focus on bacteria infections that are increasingly resistant to all known classes of antibiotics and which can cause a significant threat to patients, particularly those in hospital intensive care units.
Dr Patrick Vallance, senior vice president, GlaxoSmithKline drug discovery said: "GSK is committed to identifying and progressing novel antibacterials that address this rapidly emerging public health threat.
“This agreement with DTRA provides a substantial resource towards address the challenges of this area and will enable us to accelerate the delivery of new gram negative antibacterials for patients."
September 21 2007
Related Links
GlaxoSmithKline
Bookmark with:
- Digg
- Reddit
- Del.icio.us
- Facebook
- Newsvine
Sign Up to Exec UK now for FREE!